一种具有突出的静血效应的热敏水凝通过抗阿诺基斯抗药物防止瘤复发
Yang Liu1,2, Lei Ding3,4, Gaojie Chen1,2
1Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People's Republic of China.
Journal of nanobiotechnology
|August 20, 2024
概括
这项研究引入了一种新的纳米酶-水凝系统,用于对抗抗氧化物耐药 (AR) 膀癌细胞. 该系统削弱AR,抑制转移,并通过将增强的化学动力学治疗与血液静止结合起来,防止手术后瘤复发.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 瘤细胞中的阿诺基斯抗性 (AR) 促进转移和脱落后的复发.
- 目前的治疗方法缺乏有效的策略来防止瘤细胞扩散和术后复发.
研究的目的:
- 开发一种新的纳米酶-系统 (H@DMSN-Cu@GOx/PEG),用于增强化学动力学疗法 (ECDT) 和手术内静血.
- 研究该系统在减弱AR,抑制膀癌细胞迁移和入侵以及预防术后瘤复发方面的有效性.
主要方法:
- 制造一个纳米复合物 (DMSN-Cu@GOx/PEG) 与Cu2+和葡萄糖氧化酶 (GOx) 在一个树突性半孔纳米框架内,然后进行PEGylation.
- 将纳米复合材料封装成一个热敏水凝 (H@DMSN-Cu@GOx/PEG).
- 评估系统的过氧酶 (POD) 和酶 (CAT) 活动,ROS生成,缺氧缓解,以及膀癌细胞上皮质-介质细胞转换 (EMT) 的抑制,以及体内静血和抗瘤复发评估.
主要成果:
- 该H@DMSN-Cu@GOx/PEG水凝在体温下表现出有效的静血和凝,在手术后形成了一层保护膜.
- 该纳米酶成分表现出高的POD活性来增加细胞内ROS,削弱AR,以及高的CAT活性来将H2O2转化为O2,缓解瘤缺氧.
- 在体内研究证实了该系统降低HIF-1α调节,抑制EMT,抑制瘤细胞迁移和入侵,并防止复发的能力.
结论:
- 开发的纳米酶-凝系统有效地抑制了膀癌细胞中阿诺基斯的抵抗力.
- 这种新的纳米系统和水凝为手术内静血和预防手术切除后瘤复发提供了一个有希望的策略.
- 这项研究开创了以树突性半孔基纳米反应器为基础的使用,用于治疗膀癌在手术后复发.
相关概念视频
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
927
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927